Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Barry, Mirtsching"'
Autor:
Barry Mirtsching, Susan Luedke, Michael Rader, Howard Ozer, Lyndah Dreiling, Beiying Ding, Stephen J. Noga
Publikováno v:
The Oncologist. 12:484-494
The impact of first- and subsequent-cycle growth factor use in the community setting has not been studied extensively. We conducted this large, prospective, noncomparative study to assess neutropenia and related complications in patients receiving my
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7707744c4c165a4af05ffbd2bb3a307
https://doi.org/10.1634/theoncologist.12-4-484
https://doi.org/10.1634/theoncologist.12-4-484
Publikováno v:
Clinical breast cancer. 11(2)
Introduction Weekly administration of nanoparticle albumin-bound ( nab ) paclitaxel as a first-line treatment for metastatic breast cancer (MBC) has not been fully investigated. The addition of trastuzumab, a monoclonal antibody against human epiderm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::641fb12eec20aeb7224ff50c573f523e
https://pubmed.ncbi.nlm.nih.gov/21569998
https://pubmed.ncbi.nlm.nih.gov/21569998
Autor:
Saroj, Vadhan-Raj, Barry, Mirtsching, Veena, Charu, Dixon, Terry, Gregory, Rossi, Dianne, Tomita, William P, McGuire
Publikováno v:
The journal of supportive oncology. 1(2)
The objective of this ongoing trial is to study the ability of darbepoetin alfa to reverse chemotherapy-induced anemia in cancer patients, and to relate improvement in hemoglobin with changes in fatigue and functional capacity. Eligible subjects had
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b383c0cedc942b7b8ee6844d7d25338e
https://pubmed.ncbi.nlm.nih.gov/15352656
https://pubmed.ncbi.nlm.nih.gov/15352656
Autor:
Barry, Mirtsching, Veena, Charu, Saroj, Vadhan-Raj, Alan B, Colowick, Gregory, Rossi, Dianne, Tomita, William P, McGuire
Publikováno v:
Oncology (Williston Park, N.Y.). 16(10 Suppl 11)
The safety and efficacy of darbepoetin alfa (Aranesp) at 3.0 microg/kg administered every 2 weeks and recombinant human erythropoietin (rHuEPO) given as 40,000 U weekly or 150 U/kg three times weekly were evaluated by pooling data from three darbepoe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::813fecccbf16ed75212942b7cdff08e1
https://pubmed.ncbi.nlm.nih.gov/12435171
https://pubmed.ncbi.nlm.nih.gov/12435171
Autor:
Lyndah Dreiling, Howard Ozer, Stephen J. Noga, Beiying Ding, Michael Rader, Susan Luedke, Barry Mirtsching
Publikováno v:
The Oncologist. 12:1465-1466
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40e293f5c71f064a34c96f67e55c5196
https://doi.org/10.1634/theoncologist.12-12-1465
https://doi.org/10.1634/theoncologist.12-12-1465
Autor:
Dianne Tomita, Peter T. Silberstein, Lee S. Schwartzberg, Ronald Burkes, Barry Mirtsching, Timothy Rearden, Tom Lillie
Publikováno v:
European Journal of Cancer Supplements. 5:154
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::426e774cb343e10ce13a3ca4b9f35a85
https://doi.org/10.1016/s1359-6349(07)70660-2
https://doi.org/10.1016/s1359-6349(07)70660-2
Autor:
Barry Mirtsching, Lorrin Yee, Ronald Burkes, Veena Charu, Timothy Rearden, Hung Lam, Peter T. Silberstein, Lee S. Schwartzberg, Tom Lillie
Publikováno v:
Blood. 108:1306-1306
Cancer pts with CIA may experience decreased quality of life (QOL) and may require red blood cell transfusions (TFNs). DA increases hemoglobin (Hb) to levels recommended by practice guidelines (11 to 13g/dL), thereby reducing TFN requirements and imp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d82bbd99f2142976fc44fedc11aba350
https://doi.org/10.1182/blood.v108.11.1306.1306
https://doi.org/10.1182/blood.v108.11.1306.1306
Autor:
Dianne Tomita, Barry Mirtsching, Saroj Vadhan-Raj, Greg Rossi, Stephanie A. Gregory, Douglas W. Blayney
Publikováno v:
Blood. 104:3296-3296
Introduction: Chemotherapy-induced anemia is common in patients (pts) undergoing chemotherapy for Non Hodgkin’s Lymphoma (NHL). Darbepoetin alfa (DA) has been shown to increase hemoglobin (Hb), decrease transfusions, and reduce fatigue. NCCN eviden
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d21fbebac6306708477876e4010a885
https://doi.org/10.1182/blood.v104.11.3296.3296
https://doi.org/10.1182/blood.v104.11.3296.3296
Autor:
Tom Lillie, Barry Mirtsching, Lee S. Schwartzberg, Ronald Burkes, Lorrin Yee, Peter T. Silberstein, Amy Inamoto, Timothy Rearden
Publikováno v:
BMC Cancer, Vol 10, Iss 1, p 581 (2010)
BMC Cancer
BMC Cancer
Background Chemotherapy-induced anemia (CIA) is responsive to treatment with erythropoiesis-stimulating agents (ESAs) such as darbepoetin alfa. Administration of ESAs on a synchronous schedule with chemotherapy administration could benefit patients b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e18f9dc12d20debf7cae23760f5d3b9